Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors Aug. 3, 2021 No Comments
U.K. MHRA clears initiation of first-in-human study of HMBD-001 in advanced cancers Aug. 2, 2021 No Comments
New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC July 29, 2021 No Comments
Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors July 29, 2021 No Comments
Responses seen with personalized neoantigen peptide vaccine in NSCLC patients with EGFR mutations July 27, 2021 No Comments
RSS